Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its bread-and-butter antirival franchise with an eye on the potential of its long-acting HIV med lenacapavir.

But with its cell therapy unit stalling and antibody-drug conjugate Trodelvy facing challenges, the company’s oncology ambitions were brought back under the spotlight during its third-quarter earnings report.